images

India’s Push for Self-Reliance in Penicillin Production

30 August, 2025 991 Views

For decades, India has been known as the “pharmacy of the world” producing affordable medicines for global markets. India is the third largest producer of drugs and pharmaceuticals by its volume, with a 20% global share in the export of generic drugs. But beneath that strength, for some of the most basic building blocks of antibiotics, such as Penicillin G, India has been entirely dependent on imports.

This dependency creates a vulnerable situation as a single disruption in the supply from a dominant global producer could ripple through hospitals, pharmacies and public health systems. 

Back in late 1990s and early 2000s, as it was harder to compete with cheaper imports from China, India shut down most of its fermentation based antibiotic facilities. As a result, India known as the world’s leading generic drug manufacturer was ironically importing almost 100 % of it’s Penicillin G, erythromycin thiocyanate and clavulanic acid requirements.

In recent years, the rising demand, combined with limited production concentrated in only a handful of countries has left many regions struggling to secure steady supplies. 

When availability drops, it isn’t just a supply chain issue — it becomes a public health crisis, jeopardizing millions of lives.

The COVID-19 pandemic further exposed this fragility, when global disruptions highlighted how over-dependence on one geography could compromise national health security. 

Looking at the risks, India has finally launched a bold plan to bring back domestic penicillin production after nearly three decades of absence.

The Aurobindo Pharma’s integrated Penicillin-G (Pen-G) complex at Kakinada, Andhra Pradesh, a 15,000 MTPA facility designed to feed its own formulations and supply Indian and global markets, is the flagship example of this. The move isn’t just about reducing imports but it’s also about resilience, price stability and setting example for other nations grappling with similar pharmaceutical supply chain challenges. 

The Policy Push: 

India’s Production Linked Incentive (PLI) Scheme 

After the pandemic, to address these risks, the Government of India launched a Production Linked Incentive (PLI) Scheme for bulk drugs in 2021. The government identified critical Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) where India was fully dependent on imports. Penicillin G was at the top of the list.

According to the PLI scheme, companies producing these critical inputs in India would receive multi-year incentives linked to incremental sales. The PLI scheme was designed with a clear vision :  

  • It offered investors long-term demand assurance.  
  • It focused on critical bottlenecks rather than diluting resources.  
  • It established a defined six-year window for companies to scale and build global competitiveness. 

 

This policy paved the way for Aurobindo Pharma to launch one of the largest antibiotic manufacturing initiatives India has witnessed in decades. 

Bridging the Gap with Formulations 

Reviving Penicillin G production is only the first step. The real measure of impact lies in ensuring that these raw materials are converted into accessible, reliable medicines that reach the patients at the right time. 

Bulk Pen-G production is the foundation but the Formulations are the bridge between industrial production and patient care. By securing the base of the supply chain, India is indirectly strengthening the last mile of access. It is ensuring that improved availability of Pen-G does not remain confined to warehouses but is translated into affordable, life-saving injections in hospitals around the world. 

India’s growing formulation capacity places it in a unique position. By converting domestically produced Pen-G into injectable antibiotics at scale, Indian manufacturers help:  

  • Stabilize global supply chains, reducing dependence on single-source producers.  
  • Support global health initiatives, especially in regions struggling with shortages.  
  • Ensure affordability, keeping life-saving antibiotics accessible to vulnerable populations. 

 

A reliable domestic supply of Pen-G empowers formulation manufacturers with major advantages : 

1. When raw material availability is secure, formulation plants can operate without the fear of sudden stoppages which helps them ensure that hospitals and health systems have a steady flow of injectable antibiotics at the point of care. 

2. Global shortages of Pen-G often drives up prices, making finished formulations more expensive and less accessible. Stable domestic production helps in keeping the cost predictable, ensuring that the most vulnerable populations are not priced out of essential medicines. 

3. A strong foundation in bulk drug manufacturing reduces dependency on imports. Factors like geopolitical, logistical or economic are less likely to disrupt the availability of finished formulations. This is critical for national health security and also strengthens India’s position as a global supplier of affordable generics. 

4. Interruptions in supply can have devastating consequences, including preventable maternal and child deaths. Ensuring a stable supply of Pen-G formulations has a direct, measurable impact on global health outcomes. 

Conclusion : 

The revival of Penicillin-G in India is more than an industrial win, it’s a story of resilience and foresight. 

For India, it secures antibiotic self-reliance. For the world, it diversifies supply in the face of global shortages. 

And for the pharmaceutical ecosystem, it creates the most critical link specially for formulation manufacturers who transform raw Pen-G into life-saving medicines, ensuring the revival reaches patients, not just production charts. 

The big question remains : 

Can India’s focused model for Pen-G become the blueprint for tackling other global drug shortages and dependencies?